# Acalabrutinib versus venetoclax plus obinutuzumab in treatment-naive chronic lymphocytic leukemia: A real-world propensity score-matched study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/acalabrutinib-versus-venetoclax-plus-obinutuzumab-in-treatment-naive-chronic/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Chieh‐Lin Jerry Teng,Yu-Min Liao,B.-C. Liao |
| Citations | 0 |
| DOI | 10.1182/blood-2025-5662 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://ashpublications.org/blood/article-pdf/146/Supplement 1/5662/2462280/blood-8409-main.pdf |
| OpenAlex ID | https://openalex.org/W4417018452 |
| Type | conference-abstract |
| Year | 2025 |

## Paper authors

- [B.-C. Liao](https://scholariq.org/researchers/b-c-liao/)

## Paper journal

- [Blood](https://scholariq.org/journals/blood/)

## Paper primary topic

- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)

## Paper topics

- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Phagocytosis and Immune Regulation](https://scholariq.org/topics/phagocytosis-and-immune-regulation/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.